The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case–control study
详细信息 查看全文
- 作者：Andrea De Luca (25) (34)
Katleen de Gaetano Donati (26)
Manuela Colafigli (26)
Alessandro Cozzi-Lepri (27)
Amalia De Curtis (28)
Andrea Gori (29)
Laura Sighinolfi (30)
Andrea Giacometti (31)
Maria Rosaria Capobianchi (32)
Alessandro D’Avino (26)
Licia Iacoviello (28)
Roberto Cauda (26)
Antonella D’Arminio Monforte (33) - 关键词：Biomarkers ; Cardiovascular disease ; HIV ; hsCRP
- 刊名：BMC Infectious Diseases
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：13
- 期：1
- 全文大小：231KB
- 参考文献：1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. / N Engl J Med 1998, 338:853-60. CrossRef
2. Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, Natarajan V, Rehm C, Hadigan C, Sereti I: Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. / AIDS 2010, 24:1509-517. CrossRef
3. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Schouten JT, Smieja M, Working Group 2: Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. / Circulation 2008, 118:e29-e35. CrossRef
4. Triant VA, Lee H, Hadigan C, Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. / J Clin Endocrinol Metab 2007, 92:2506-512. CrossRef
5. Law MG, Friis-M?ller N, El-Sadr WM, Weber R, Reiss P, D’Arminio Monforte A, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD, D:A:D Study Group: The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. / HIV Med 2006, 7:218-30. CrossRef
6. Maggi P, Quirino T, Ricci E, De Socio GV, Gadaleta A, Ingrassia F, Perilli F, Lillo A, Bonfanti P: Cardiovascular risk assessment in antiretroviral-na?ve HIV patients. / AIDS Patient Care STDS 2009, 23:809-13. CrossRef
7. Teitel JM, Shore A, Read SE, Schiavone A: Immune function of vascular endothelial cells is impaired by HIV. / J Infect Dis 1989, 160:551-52. CrossRef
8. Zietz C, Hotz B, Stürzl M, Rauch E, Penning R, L?hrs U: Aortic endothelium in HIV-1 infection: chronic injury, activation, and increased leukocyte adherence. / Am J Pathol 1996, 149:1887-898.
9. de Gaetano DK, Rabagliati R, Iacoviello L, Cauda R: HIV infection, HAART, and endothelial adhesion molecules: current perspectives. / Lancet Infect Dis 2004, 4:213-22. CrossRef
10. de Gaetano DK, Rabagliati R, Tumbarello M, Tacconelli E, Amore C, Cauda R, Iacoviello L: Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. / AIDS 2003, 17:765-68. CrossRef
11. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, Maa JF, Hodder S: Coronary heart disease in HIV-infected individuals. / J Acquir Immune Defic Syndr 2003, 33:506-12. CrossRef
12. Bergersen BM: Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. / Drugs 2006, 66:1971-987. CrossRef
13. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M, Swiss HIV Cohort Study: Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. / J Infect Dis 2002, 185:456-62. CrossRef
14. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH, ACTG 5152s Study Team: Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. / J Am Coll Cardiol 2008, 52:569-76. CrossRef
15. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-M?ller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J: Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. / J Infect Dis 2010, 201:318-30. CrossRef
16. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV: Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case–control study nested within the French Hospital Database on HIV ANRS cohort CO4. / Arch Intern Med 2010, 170:1228-238. CrossRef
17. Friis-M?ller N, Weber R, Reiss P, Thiébaut R, Kirk O, D’Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD, DAD study group: Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. / AIDS 2003, 17:1179-193. CrossRef
18. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. / Circulation 2001, 104:257-62. CrossRef
19. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS: HIV Outpatient Study (HOPS) investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. / Lancet 2002, 360:1747-748. CrossRef
20. Friis-M?ller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD, DAD Study Group: Class of antiretroviral drugs and the risk of myocardial infarction. / N Engl J Med 2007, 356:1723-735. CrossRef
21. Wilson SL, Scullard G, Fidler SJ, Weber JN, Poulter NR: Effects of HIV status and antiretroviral therapy on blood pressure. / HIV Med 2009, 10:388-94. CrossRef
22. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D’Arminio Monforte A, Friis-M?ller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD, D:A:D Study Group: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. / Lancet 2008, 371:1417-426. CrossRef
23. Behrens GM, Reiss P: Abacavir and cardiovascular risk. / Curr Opin Infect Dis 2010, 23:9-4. CrossRef
24. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. / Circulation 2003, 107:363-69. CrossRef
25. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators: C-reactive protein levels and outcomes after statin therapy. / N Engl J Med 2005, 352:20-8. CrossRef
26. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamensky G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group: Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): aretrospective analysis. / Circulation 2009, 120:2188-196. CrossRef
27. Lowe GD: Fibrin D-dimer and cardiovascular risk. / Semin Vasc Med 2005, 5:387-98. CrossRef
28. Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, van Gilst WH, Moore JH: Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits. / J Thromb Haemost 2007, 5:313-20. CrossRef
29. Zakynthinos E, Pappa N: Inflammatory biomarkers in coronary artery disease. / J Cardiol 2009,53(3):317-33. CrossRef
30. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F, Centers for Disease Control and Prevention: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. / Circulation 2003, 107:499-11. CrossRef
31. Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, Neuhaus J, Paton NI, Friis-Moller N, Lampe F, Liappis AP, Neaton JD, INSIGHT SMART Study Group: Lipoprotein particle subclasses, cardiovascular disease and HIV infection. / Atherosclerosis 2009, 207:524-29. CrossRef
32. Mastroianni CM, Lichtner M, Mengoni F, D’Agostino C, d’Ettorre G, Forcina G, Santopadre P, Massetti AP, Vullo V: Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients. / Clin Immunol 2000, 95:212-17. CrossRef
33. Tungsiripat M, Adell J, McComsey GA: Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. / Clin Infect Dis 2009, 49:1119-127. CrossRef
34. Duprez DA, Neuhaus J, Kuller LH, / et al.: Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. / PLoS One 2012, 7:e44454. CrossRef
35. Di Giambenedetto S, Bracciale L, Colafigli M, Cattani P, Pinnetti C, Bacarelli A, Prosperi M, Fadda G, Cauda R, De Luca A: Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. / Antivir Ther 2007, 12:835-39.
36. d’Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral na?ve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Na?ve Patients. / AIDS 2000, 14:499-07. CrossRef
37. Sasieni P: A note on the presentation of matched case–control data. / Stat Med 1992, 11:617-20. CrossRef
38. Greenland S, Schwartzbaum JA, Finkle WD: Problems due to small samples and sparse data in conditional logistic regression analysis. / Am J Epidemiol 2000, 151:531-39. CrossRef
39. Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. / Biometrics 1986, 42:121-30. CrossRef
40. Baker J, Ayenew W, Quick H, Hullsiek KH, Tracy R, Henry K, Duprez D, Neaton JD: High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. / J Infect Dis 2010, 201:285-92. CrossRef
41. Noursadeghi M, Miller RF: Clinical value of C-reactive protein measurements in HIV-positive patients. / Int J STD AIDS 2005, 16:438-41. CrossRef
42. Masiá M, Bernal E, Padilla S, Graells ML, Jarrín I, Almenar MV, Molina J, Hernández I, Gutiérrez F: The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. / Atherosclerosis 2007,195(1):167-71. CrossRef
43. Guimar?es MM, Greco DB, Figueiredo SM, Fóscolo RB, Oliveira AR Jr, Machado LJ: High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection. / Atherosclerosis 2008,201(2):434-39. CrossRef
44. Triant VA, Meigs JB, Grinspoon SK: Association of C-reactive protein and HIV infection with acute myocardial infarction. / J Acquir Immune Defic Syndr 2009, 51:268-73. CrossRef
45. Boger MS, Shintani A, Redhage LA, Mitchell V, Haas DW, Morrow JD, Hulgan T: Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. / J Acquir Immune Defic Syndr 2009,52(4):480-87. CrossRef
46. Erzen B, Sabovic M, Sebestjen M, Keber I, Poredos P: Interleukin-6 correlates with endothelial dysfunction in young post-myocardial infarction patients. / Cardiology 2007,107(2):111-16. CrossRef
47. Blann AD, Nadar SK, Lip GY: The adhesion molecule P-selectin and cardiovascular disease. / Eur Heart J 2003, 24:2166-179. CrossRef
48. Panel on Antiretroviral Guidelines for Adults and Adolescents: / Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 11th 2013. Last updated March 27th 2012 Available at . Accessed January 11th 2013. Last updated March 27th 2012
49. Ben-Yehuda O: High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients. / J Am Coll Cardiol 2007, 49:2139-141. CrossRef
50. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J, Collaboration Emerging Risk Factors: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. / Lancet 2010,375(9709):132-40. CrossRef
51. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/13/414/prepub - 作者单位：Andrea De Luca (25) (34)
Katleen de Gaetano Donati (26)
Manuela Colafigli (26)
Alessandro Cozzi-Lepri (27)
Amalia De Curtis (28)
Andrea Gori (29)
Laura Sighinolfi (30)
Andrea Giacometti (31)
Maria Rosaria Capobianchi (32)
Alessandro D’Avino (26)
Licia Iacoviello (28)
Roberto Cauda (26)
Antonella D’Arminio Monforte (33)
25. University Division of Infectious Diseases, University Hospital of Siena, Siena, Italy
34. Istituto di Clinica delle Malattie Infettive, Università Cattolica del Sacro Cuore, Largo F Vito 1, 00168, Roma, Italy
26. Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
27. Research Department of Infection and Population Health, University College London, London, UK
28. Department of Epidemiology and Prevention, IRCCS Istituto Neurologico Mediterraneo Nueromed, Laboratory of Molecular and Nutritional Epidemiology, Pozzilli (IS), Italy
29. Department of Infectious Diseases, Hospital of Monza, Monza, Italy
30. Department of Infectious Diseases, Hospital of Ferrara, Ferrara, Italy
31. Department of Infectious Diseases, Marche Polytechnic University, Ancona, Italy
32. Department of Virology, IRCCS Ospedale Lazzaro Spallanzani, Rome, Italy
33. Institute of Infectious and Tropical Medicine, University of Milan, Milan, Italy
文摘
Background Elevated high-sensitivity C-reactive protein (hsCRP) increases the risk of cardiovascular disease (CVD) in the general population, but its role as a predictive marker in HIV-positive patients remains unclear. Aim of the study was to evaluate whether hsCRP or other biomarkers are independent predictors of CVD risk in HIV-infected patients. Methods Retrospective, nested case–control study. HIV-positive men and women (35-9?years of age) receiving combination antiretroviral therapy (cART) were included. Cases (n = 35) had a major CVD event. Controls (n = 74) free from CVD events for at least 5?years from starting ART were matched on diabetes and smoking. HsCRP, D-dimer, P-selectin, interleukin-6 (IL-6), tissue plasminogen activator, plasminogen activator inhibitor-1 levels were measured. Results High hsCRP was associated with CVD risk, independently of traditional cardiovascular risk factors, HIV replication and the type of ART received at the time of sampling (adjusted odds ratio 8.00 [1.23-51.94] comparing >3.3?mg/L with <0.9?mg/L; P = 0.03). Higher IL-6 and P-selectin levels were also independently associated with increased CVD risk, although the association was weaker than for hsCRP. Higher total cholesterol and lower HDL cholesterol increased CVD risk, independent of hsCRP. Conclusion hsCRP may be a useful additional biomarker to predict CVD risk in HIV-infected patients receiving cART.